Advances in Anticancer Immunotoxin Therapy

Overview

Journal Oncologist

Publisher Oxford University Press

Specialty Oncology

Date 2015 Jan 7

PMID 25561510

Citations 93

Authors

Christine Alewine

Raffit Hassan

Ira Pastan

Affiliations

Soon will be listed here.

Abstract

Immunotoxins are a novel class of antibody-conjugated therapeutics currently in clinical development for a variety of malignancies. They consist of an antibody-based targeting domain fused to a bacterial toxin payload for cell killing. Immunotoxins kill cells by inhibiting protein synthesis, a unique mechanism of action that is toxic to both dividing and nondividing cells. Recent advances in the design and administration of immunotoxins are overcoming historical challenges in the field, leading to renewed interest in these therapeutics.

Citing Articles

The immunotoxin targeting PRLR increases tamoxifen sensitivity and enhances the efficacy of chemotherapy in breast cancer.

Zhang J, Liu J, Yue Y, Wang L, He Q, Xu S J Exp Clin Cancer Res. 2024; 43(1):173.

PMID: 38898487 PMC: 11188579. DOI: 10.1186/s13046-024-03099-4.

Can antibodies be "vegan"? A guide through the maze of today's antibody generation methods.

Dubel S MAbs. 2024; 16(1):2343499.

PMID: 38634488 PMC: 11028021. DOI: 10.1080/19420862.2024.2343499.

In vitro and in vivo anti-tumor effect of Trichobakin fused with urokinase-type plasminogen activator ATF-TBK.

Pham D, Pham T, Bui T, Britikova E, Britikov V, Bocharov E Mol Biol Rep. 2024; 51(1):130.

PMID: 38236367 DOI: 10.1007/s11033-023-09036-6.

Novel Anti-Mesothelin Nanobodies and Recombinant Immunotoxins with Exotoxin Catalytic Domain for Cancer Therapeutics.

Nguyen M, Kim D, Shim H, Ta H, Vu T, Nguyen T Mol Cells. 2023; 46(12):764-777.

PMID: 38052492 PMC: 10701305. DOI: 10.14348/molcells.2023.0155.

Bringing enzymes to the proximity party.

Tender G, Bertozzi C RSC Chem Biol. 2023; 4(12):986-1002.

PMID: 38033727 PMC: 10685825. DOI: 10.1039/d3cb00084b.

References

Chandramohan V, Sampson J, Pastan I, Bigner D . Toxin-based targeted therapy for malignant brain tumors. Clin Dev Immunol. 2012; 2012:480429. PMC: 3287048. DOI: 10.1155/2012/480429. View

Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G . Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma. Neuro Oncol. 2010; 12(8):871-81. PMC: 2940677. DOI: 10.1093/neuonc/nop054. View

Hassan R, Bullock S, Premkumar A, Kreitman R, Kindler H, Willingham M . Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res. 2007; 13(17):5144-9. DOI: 10.1158/1078-0432.CCR-07-0869. View

Einama T, Homma S, Kamachi H, Kawamata F, Takahashi K, Takahashi N . Luminal membrane expression of mesothelin is a prominent poor prognostic factor for gastric cancer. Br J Cancer. 2012; 107(1):137-42. PMC: 3389425. DOI: 10.1038/bjc.2012.235. View

Vallera D, Chen H, Sicheneder A, Panoskaltsis-Mortari A, Taras E . Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy. Leuk Res. 2009; 33(9):1233-42. PMC: 2738628. DOI: 10.1016/j.leukres.2009.02.006. View

Chandramohan V, Bao X, Keir S, Pegram C, Szafranski S, Piao H . Construction of an immunotoxin, D2C7-(scdsFv)-PE38KDEL, targeting EGFRwt and EGFRvIII for brain tumor therapy. Clin Cancer Res. 2013; 19(17):4717-27. PMC: 3766439. DOI: 10.1158/1078-0432.CCR-12-3891. View

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

Antignani A, Fitzgerald D . Immunotoxins: the role of the toxin. Toxins (Basel). 2013; 5(8):1486-502. PMC: 3760048. DOI: 10.3390/toxins5081486. View

Collier R . Effect of diphtheria toxin on protein synthesis: inactivation of one of the transfer factors. J Mol Biol. 1967; 25(1):83-98. DOI: 10.1016/0022-2836(67)90280-x. View

10.

Hassan R, Miller A, Sharon E, Thomas A, Reynolds J, Ling A . Major cancer regressions in mesothelioma after treatment with an anti-mesothelin immunotoxin and immune suppression. Sci Transl Med. 2013; 5(208):208ra147. PMC: 6369691. DOI: 10.1126/scitranslmed.3006941. View

11.

Wang H, Song S, Kou G, Li B, Zhang D, Hou S . Treatment of hepatocellular carcinoma in a mouse xenograft model with an immunotoxin which is engineered to eliminate vascular leak syndrome. Cancer Immunol Immunother. 2007; 56(11):1775-83. PMC: 11030707. DOI: 10.1007/s00262-007-0321-4. View

12.

Selvaggi K, Saria E, Schwartz R, Vlock D, Ackerman S, Wedel N . Phase I/II study of murine monoclonal antibody-ricin A chain (XOMAZYME-Mel) immunoconjugate plus cyclosporine A in patients with metastatic melanoma. J Immunother Emphasis Tumor Immunol. 1993; 13(3):201-7. DOI: 10.1097/00002371-199304000-00007. View

13.

Zhou H, Ekmekcioglu S, Marks J, Mohamedali K, Asrani K, Phillips K . The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. J Invest Dermatol. 2012; 133(4):1052-62. PMC: 3600159. DOI: 10.1038/jid.2012.402. View

14.

LoRusso P, Lomen P, Redman B, Poplin E, Bander J, Valdivieso M . Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer. Am J Clin Oncol. 1995; 18(4):307-12. DOI: 10.1097/00000421-199508000-00008. View

15.

Kuan C, Pai L, Pastan I . Immunotoxins containing Pseudomonas exotoxin that target LeY damage human endothelial cells in an antibody-specific mode: relevance to vascular leak syndrome. Clin Cancer Res. 1995; 1(12):1589-94. View

16.

Mariotti J, Taylor J, Massey P, Ryan K, Foley J, Buxhoeveden N . The pentostatin plus cyclophosphamide nonmyeloablative regimen induces durable host T cell functional deficits and prevents murine marrow allograft rejection. Biol Blood Marrow Transplant. 2010; 17(5):620-31. PMC: 3061246. DOI: 10.1016/j.bbmt.2010.11.029. View

17.

Verhaak R, Hoadley K, Purdom E, Wang V, Qi Y, Wilkerson M . Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010; 17(1):98-110. PMC: 2818769. DOI: 10.1016/j.ccr.2009.12.020. View

18.

Siegall C, Liggitt D, Chace D, Tepper M, Fell H . Prevention of immunotoxin-mediated vascular leak syndrome in rats with retention of antitumor activity. Proc Natl Acad Sci U S A. 1994; 91(20):9514-8. PMC: 44843. DOI: 10.1073/pnas.91.20.9514. View

19.

Chang K, Pai L, Pass H, Pogrebniak H, Tsao M, Pastan I . Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol. 1992; 16(3):259-68. DOI: 10.1097/00000478-199203000-00006. View

20.

Kreitman R, Tallman M, Robak T, Coutre S, Wilson W, Stetler-Stevenson M . Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol. 2012; 30(15):1822-8. PMC: 3383181. DOI: 10.1200/JCO.2011.38.1756. View